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Abstract: Herbal medicines in treatment of cancer as complementary and alternative therapy are accepted increasingly 
with growing scientific evidences of biomedical research and clinical trials. Anticancer drugs discovered from herbal 
medicines have a long history and some of them have been used in clinical setting as the conventional anticancer drugs. 
Actually, herbal medicines are a source for anticancer drug discovery and drug development. Recently, research 
continuously focuses on clues from traditional use of herbal medicines to develop new anticancer drugs in single pure 
compounds. On the other hand, standardized various extracts or fractions with anticancer effects or with adjuvant therapy 
in cancer treatment coming from single or mixed herbs are also accepted forms as dietary supplements and botanical drug 
products in the US for current statutory regulations. In the present paper, we analyzed the patented agents in the US from 
herbal medicines in recent ten years, both as potential anticancer extracts/fractions (containing multi-components) and 
single pure compound(s) that act as new anticancer substances. This review also highlighted the advances in knowledge 
about quality control, safety, efficacy and recent progress in anticancer candidates in patents of botanical drug products 
from herbal medicines. 
Keywords: Anticancer drugs, antimetastasis drugs, complementary and alternative medicines, Chinese medicines, herbal 
medicine, patent. 
INTRODUCTION 
 Anticancer drugs discovered from herbal medicines have 
a long history and plant-derived compounds have been an 
important source of several useful anti-cancer agents in 
clinical practice, such as vinblastine, vincristine, the camp-
tothecin derivatives, topotecan and irinotecan, etoposide, 
which are isolated or derived from Catharanthus roseus G. 
Don. (Apocynaceae), Camptotheca acuminata Decne (Nys-
saceae), Podophyllum peltatum Linnaeus (Podophyllaceae) 
and Taxus brevifolia Nutt. (Taxaceae) [1]. In recent years, 
traditional medicine, such as Chinese medicine, Kampo 
medicine, Ayurveda and so on, are popular treatment for 
cancer in Asian countries, and these approaches are also 
accepted increasingly as complementary and alternative 
therapies for cancer in the rest of the world. A number of 
scientific evidences at molecular mechanisms and clinical 
trial showed they have anticancer potential. Most of the 
medications in traditional medicine are derived from plants, 
so we call them herbal medicines.  
 In Asian countries and regions, such as mainland China, 
Hong Kong, Taiwan, Japan and Korea, Chinese Medicines 
are regarded as drugs in their statutory regulations and used 
in daily cancer clinical practice, for example, herbal 
medicines are some forms of the drugs listed in Chinese and  
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Japanese Pharmacopoeias. It is a common model for herbal 
medicine studies in recent years, the goal of research is to 
“dig out” major active single herb(s) in a composite formula 
for some diseases and further explore active compound(s) in 
the single herb(s), but in daily traditional medicine practice, 
practitioners rarely use a pure compound to treat diseases, 
but use a combination of single herbs to mix together (so 
called Fufang, or composite formula). FDA policy about 
products derived from herbal medicines regards them to be 
dietary supplements and botanical drug products, reflecting 
that FDA recognized the wisdom, experiences and existing 
problems in herbal medicines for its single and combination 
use.  
 In this review, we analyzed anticancer candidates in 
patents of dietary supplements and botanical drug products 
from herbal medicines and summarized current progress 
thereof. We mainly analyzed parts of recent ten years US 
patents in this study, including those that have been 
approved and that are under application. The criteria for the 
selection of the patents included are as follows, first, the 
patent should describe a compound or an extract that is 
originally isolated from a herb or medical plant; second, the 
patented product should be described as an anti-cancer agent, 
or a complement or supplement to cancer treatment agent; 
and finally, in http://www.freepatentsonline.com/, the 
relative score of the searched item to the keywords, herbal 
medicine and cancer, should be in the range from 10 to 1000. 
And we included some patents from other countries such as 
China and Europe to give examples of the patent affairs in 
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these regions. The data is focused on the US patents (granted 
or under application) in botanical drugs in the past ten years, 
and retrieved the data from www.uspto.gov, http:ep. 
espacenet.com, http:www.freepatentsonline.com, http:www. 
google.compatents, http:patft.uspto.govnetahtmlPTOsearch-
bool.html, http://www.wipo.int/pctdb/en/search-simp.jsp and 
PubMed by keywords such as anticancer drugs, antime-
tastasis drugs, complementary and alternative medicines, 
Chinese medicines, patents, herbal medicines. We also make 
a research in the website http://www.clinicaltrial.gov to get 
some information about clinical trial of herbal medicines in 
the treatment of cancer. Finally, we discussed the advances 
in knowledge about quality control, safety, efficacy and 
recent progress in anticancer candidates in patents of dietary 
supplements and botanical drug products from herbal 
medicines. 
CLAIMING ANTICANCER PROPERTIES OF 
SINGLE PURE COMPOUND FROM HERBAL 
MEDICINES 
 Cancer has become a leading cause of death in the world 
because changed disease spectrum by social and environ-
mental risk factors [2]. Cancer is a series of malignant 
diseases with multiple pathological stages (e.g. cancer initia-
tion, promotion and progression) and involved in multiple 
factors (genetic, environmental, biological, chemical, 
physical and psychological factors). There are more than a 
hundred distinct types of malignancies. Cancer is charac-
terized by a rapid and uncontrolled formation of abnormal 
cells, which may mass together to form a growth of tumor, 
proliferate throughout the body and initiate abnormal growth 
at other sites. Therefore, anticancer drugs involve pharma-
cological effects of cytotoxicity, anti-proliferation, induction 
of differentiation, anti-inflammation, cell-cycle arrest, 
induction of apoptosis and/or autophagy, anti-invasion and 
anti-metastasis.  
 There is increasing interest in the identification of small 
molecules or large molecules isolated from natural botanicals 
with properties to inhibit tumor growth and metastasis. As a 
candidate, berberine isolated from coptis and other same 
genus plants has shown this potential [3]. We firstly reported 
that berberine and Coptidis Rhizoma aqueous extract 
(CRAE) with anticancer properties by its cell death induction 
and cell migration inhibition in cell models of nasopharyn-
geal carcinoma and hepatocellular carcinoma [4-6]. One US 
patent application for berberine in treating lung cancer and 
breast cancer by its cytotoxicity has been listed in Table 1 
[7]. As shown in Table 1 (single pure compound(s) from 
single medicinal herbs), we can classify the compounds into 
different categories: anticancer substances with cytotoxicity 
have saponins [8], stelleramacrin A or purified stellera-
macrin B [9], C-2 epimeric xanthones [10], angeloyl-
substituted ingenane and its derivatives [11], methyl-beta-
orcinolcarboxylat [12] and 39-desmethoxyrapamycin [13]; 
anticancer substances with inhibition of cell growth and 
induction of apoptosis have the compound isolated from 
saururus chinensis baill [14], isoindigo, indigo and indirubin 
[15], Triptolide derivatives [16], 1-propanone-1-(2,4-
dihydroxyphenyl)-3-hydroxy-3-(4?-hydroxyphenyl) [17], 
analogues of boswellic acids [18] and Scutellaria flavonoid 
organic amine derivatives [19]; anticancer substances with 
inhibition of the formation of new blood vessels of tumor 
masses, tumor cell invasion and metastasis have arsenic 
hexoxide [20], curcumin and curcumin derivatives [21]. At 
times, some pure compounds from plants seem to have 
potential in treating cancers, but it failed in clinical trial. For 
example, swainsonine is an indolizine alkaloid that has been 
isolated from numerous species of flowering plants and some 
fungi (e.g. Locoweed) and the inventors [22] were able to 
obtain stable and substantially purified crystalline chloride 
and bromide salts of swainsonine, and determine their 
structure by X-ray crystallography. Swainsonine is a golgi 
mannosidase II inhibitor which can induce hybrid-type 
glycans of cancer and then suppress various tumor types with 
direct anti-metastatic and anti-invasion effects on tumor 
cells, and other anti-cancer activities such as immune stimu-
latory effects and myeloproliferative as well as hemores-
torative activities in in vitro and in vivo studies [22-25]. A 
phase II clinical trial of GD0039 (a hydrochloride salt of 
swainsonine) in 17 patients with renal carcinoma was 
disappointing [23], while research was still showed that 
swainsonine is an anti-cancer substance with potential for 
treating gastric carcinoma [24] and glioma [25]. However, 
the patents failed in clinical trial can also provide new 
experiences in developing new anticancer drugs in the future. 
CLAIMING ANTICANCER PROPERTIES OF 
EXTRACTS OR FRACTIONS FROM HERBAL 
MEDICINES 
 In anticancer drug development by single pure compound 
in particular, governmental funders of research and pharma-
ceutical companies have spent vast amounts internationally 
on basic research, but the return on investment is 
significantly less than anticipated. The major problem 
underlying is that, as long as the anticancer drugs develop, it 
becomes more and more difficult to discover novel, 
innovative compound candidates which may have superior 
action in clinical practice. Blind synthesis and screening of 
the chemicals without any direction indicated by any 
preliminary clinical practice make the screening step become 
long and money-consuming. More and more investment is 
put into the screening step of the candidate chemicals, but 
poor and frustrated output could be found. In recent years, 
complementary and alternative therapies are highly accepted 
worldwide, in which medication is mainly botanical drug 
products from herbal medicines. These kinds of products are 
extracts/fractions (containing multi-components). With the 
changes of international food and drug regulations, espe-
cially the US regulations, and development of chemical 
analysis technologies, such as gas chromatography (GC), 
high performance liquid chromatography (HPLC) and mass 
spectroscopy (MS) can determine the precise quantity range 
of the active components in the botanical drug products. The 
good quality control of natural products from herbal 
medicines can be applied for the US patents and/or registered 
as botanical drug products (from 2004). Various extracts or 
fractions in the US patent (granted or under application) 
from single or composite medicinal herbs are listed in Table 
2. The extracts or fractions used in anticancer or anti-
metastasis from single herbs can be found from references 
26-52 in Table 2, while those from mixture of herbs can be 
found from references 53-64 in Table 2. Most of these herbs 
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Table 1. Single Pure Compound Come From Single Medicinal Herbs. 
Patent Number, 
Date of 
Publication 
Title Description of Patent Active 
Constituents 
Cancer type, 
Mechanism of 
Anticancer Action 
Reference 
US20070298132, 
12/27/2007 
Berberine as a 
selective lung cancer 
agent 
Berberine or its salts or derivatives are 
identified as the active compound for 
selectively inhibiting lung cancer, 
potentially without toxic side effects. 
Berberine Lung cancer 
cytotoxicity 
[7] 
US7514412, 
04/07/2009 
Anticancer biangeloyl 
saponins 
Novel compounds such as compounds 
designated herein as Y or Y3, Y1, Y2, Y8, 
Y9 and Y10 are disclosed. These 
compounds have anticancer activity. The 
compounds of the present invention are 
obtainable from plants or be synthesized 
chemically. 
Saponins 
isolated from 
Xanthoceras 
sorbifolia 
Various cancer 
anticancer 
[8] 
US5616609, 
04/01/1997 
Carcinostatic 
compound and 
production thereof 
Described are stelleramacrin A and 
stelleramacrin B represented by the 
following formulas (I) and (II), 
respectively: a process for the preparation 
thereof; and anticancer agents containing 
either of them as an active ingredient. 
Therapeutics for solid cancer, said 
therapeutics containing either of 
gnidimacrin or pimelea factor P.sub.2 as an 
active ingredient, are also described. 
Stelleramacrin 
A, purified 
stelleramacrin 
B, gnidimacrin 
or pimelea 
factor P.sub.2 
Gastric cancer, 
pulmonary cancer, liver 
cancer or leukemia 
cytotoxicity 
[9] 
US7592367, 
09/22/2009 
Compounds from 
Garcinia Hanburyi, 
their use in treating 
cancer and method of 
separating epimers 
thereof 
Three pairs of C-2 epimeric xanthones 
isolated from Garcinia hanburyi and 
method for efficiently separating the 
xanthone compounds. The compounds are 
useful for their anticancer effects 
C-2 epimeric 
xanthones 
Various cancer 
cytotoxicity 
[10] 
US6787161, 
09/07/2004 
Anti-cancer 
compounds 
This invention relates to a compound or 
group of compounds present in an active 
principle derived from plants of species 
Euphorbia peplus, Euphorbia hirta and 
Euphorbia drummondii. Extracts from 
these plants have been found to show 
selective cytotoxicity against several 
different cancer cell lines 
An angeloyl- 
substituted 
ingenane and its 
derivatives 
Skin cancer 
cytotoxicity 
[11] 
US20070099993, 
05/03/2007 
Antimicrobial and 
anticancer properties 
of methyl-beta-
orcinolcarboxylate 
from lichen 
(Everniastrum 
cirrhatum) 
The present invention relates to the new 
use of an already known biomolecule 
methyl-?-orcinol carboxylate of formula I 
isolated from a lichen (Everniastrum 
cirrhatum), for treating pathogenic fungal 
infections and cancers of humans. 
Methyl-beta-
orcinolcarboxyl
ate 
Various cancer 
cytotoxicity 
[12] 
US7183289, 
02/27/2007 
39-desmethoxyrapa-
mycin, compositions 
and methods of use 
thereof 
The present invention relates to the medical 
use of 39-desmethoxyrapamycin, 
particularly in the treatment of cancer 
and/or B-cell malignancies, the induction 
or maintenance of immunosuppression, 
39-
desmethoxyrapa
mycin 
Various cancer 
cytotoxicity 
[13] 
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(Table 1) Contd…. 
Patent Number, 
Date of 
Publication 
Title Description of Patent Active 
Constituents 
Cancer type, 
Mechanism of 
Anticancer Action 
Reference 
US20040024055, 
02/05/2004 
Pharmaceutical 
composition 
containing the exract 
of saururus chinensis 
baill useful as an 
anticancer agent and a 
process for the 
preparation thereof 
The carcinostatis substances HNP-98701A, HNP-
98701B and HNP-98701C of the present 
invention selectively affect cancer cell line cells 
and cause apoptosis-type cell death. 
Eepi-
manassantin A, 
and 
manassantin A 
Various cancer 
Apoptosis 
[1?] 
US6933315, 
08/23/2005 
Derivatives of 
isoindigo, indigo and 
indirubin and methods 
of treating cancer 
A compound called NATURA, which is a 
derivative of Isoindigo is useful in aiding the 
general health of a patient and specifically is 
beneficial in preventing or treating cancer. 
Isoindigo, 
indigo and 
indirubin 
Various cancer 
inhitits cell growth 
pathway 
[15] 
Us7662976, 
02/16/2010 
Triptolide derivatives 
for modulation of 
apoptosis and 
immunosuppression 
Variously substituted carbonate and carbamate 
derivatives of triptolide compounds have good 
aqueous solubility and convert to biologically 
active compounds in vivo. The prodrugs are 
useful as immunosuppressive, anti-inflammatory 
and anticancer agents. 
Triptolide 
derivatives 
Colon cancer, breast 
cancer, lung cancer, 
and prostate cancer 
Modulation of 
apoptosis and 
immunosup-pression 
[16] 
US6498195, 
12/24/2002 
Use of 1-propanone-1-
(2,4-dihydroxy-
phenyl)-3-hydroxy-3-
(4?-hydroxyphenyl) as 
an anticarcinogenic 
agent 
Compositions and methods are provided for 
prevention and treatment of cancer. The 
compositions comprise pure hydroxylated 
chalcone compounds of licorice root (Glycyrrhiza 
glabra) including 1-propanone-1-(2,4-
dihydroxyphenyl)-3-hydroxy-3-(4?-
hydroxyphenyl). 
1-propanone-1-
(2,4-dihydroxy-
phenyl)-3-
hydroxy-3-(4?-
hydroxyphenyl) 
Various cancer 
induces apoptosis, 
inhibits tumor cell 
growth, 
[17] 
US20090298938, 
12/03/2009 
Use of semi synthetic 
analogues of boswellic 
acids for anti-cancer 
activity 
The present invention relates to use of 
compounds of general formula 1 for 
anticancerous activity, wherein the said 
compound being derived semi-synthetically from 
natural triterpenoic acids known as boswellic 
acids by the induction of apoptosis thereof 
cytotoxicity and anti-cancer activity displayed by 
semi-synthetic Boswellic acids. 
Analogues of 
boswellic acids 
Various cancer 
induces apoptosis 
[18] 
US20100197619, 
08/05/2010, 
Cyclin-dependent 
protein kinases 
inhibitor of Scutellaria 
flavonoid organic 
amine derivatives, 
synthesis and use 
thereof 
The present invention provides a series of cyclin-
dependent protein kinases (Cdks) inhibitors, 
Scutellaria flavonoid organic amine derivatives, 
synthesis and use thereof. The product is 
expected to become high efficient and low 
toxicity anti-cancer drugs. 
Scutellaria 
flavonoid 
organic amine 
derivatives 
Various cancer 
Apoptosis, 
cyclin-dependent 
protein 
kinases (Cdks) 
inhibitors 
[??] 
US6589567, 
07/08/2003 
Anti-cancer therapy 
agent of arsenic 
hexoxide (As4O6) of a 
natural chemical 
substance and its 
pharmaceutical 
composition 
This invention is about the identification of the 
HD-2, a natural chemical substance that was 
separated and purified from a natural Arsenic 
hexoxide (As4O6), a natural chemical substance 
obtained from Sinsuk after eliminating the toxic 
property, has a potent anti-cancer efficacy by its 
direct cytotoxicity on tumor cells and suppresses 
the formation of new blood vessels of tumor 
masses. 
Arsenic 
hexoxide 
Various cancer 
cytotoxicity on tumor 
cells and suppresses 
the formation of new 
blood vessels of 
tumor masses 
[2?] 
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(Table 1) Contd…. 
Patent Number, 
Date of 
Publication 
Title Description of Patent Active 
Constituents 
Cancer type, 
Mechanism of 
Anticancer Action 
Reference 
US20100197584, 
08/05/2010 
Use of curcumin to 
block brain tumor 
formation in mice 
The present invention provides 
compositions and methods of using 
curcumin or curcumin derivatives or 
analogs to activate the pro-apoptotic 
enzymes caspase-3/7 in cancer cells. 
Curcumin and 
curcumin 
derivatives 
Brain tumor 
prevent tumor 
formation, or tumor cell 
invasion or metastasis 
[21] 
US6395745, 
05/28/2002 
Alkaloid halide salts 
of swainsonine and 
methods of use 
The present invention relates to stable and 
substantially purified synthetic halide salts 
of swainsonine. Golgi mannosidase II 
inhibitors such as swainsonine have cancer 
suppressing properties in a wide variety of 
tumor types including direct anti-metastatic 
and anti-invasion effects on tumor cells, 
and other anti-cancer activities such as 
immune stimulatory effects and 
myeloproliferative and hemorestorative 
activities as described herein. 
Swainsonine Various cancer 
Golgi mannosidase II 
inhibitors 
[22] 
 
Table 2. Various Extracts or Fractions Come From Single or Composite Medicinal Herbs. 
Patent Number, 
Date of Publication 
Title Description of Patent 
Extracts, 
Fractions 
and Active 
Constituents 
Cancer types, 
Mechanism of 
Anticancer Action; 
Cancer Types 
Reference 
US20100009017, 
01/14/2010 
Anticancer Methods 
Using Extracts of 
Anemarrhena 
asphodeloides Bunge 
Selective apoptotic extracts of 
Anemarrhena asphodeloides Bunge are 
provided. Also provided are methods of 
using said extracts to induce apoptosis in 
specific cells, especially in a human. 
Extracts of 
Anemarrhena 
asphodeloides 
Bunge 
Breast cancer 
Apoptosis 
 
[26] 
US6599540, 
07/29/2003 
Use of a Serenoa repens 
extract for the 
production of a 
medicament to treat 
prostate cancer 
The invention relates to the use of a lipido-
sterolic Serenoa repens extract for the 
production of a medicament which is 
administered in an isolated manner or in an 
associated manner, in a simultaneous, 
separated or staggered manner, with 
prostatectomy, radiotherapy and/or 
hormonotherapy in order to prevent and/or 
treat prostate cancer. 
Lipid-sterol 
extract 
Prostate cancer 
prevent and/or treat 
prostate cancer. 
[27] 
US20080199550, 
08/21/2008 
Novel Anticancer 
Agent, Methods for 
Obtaining the Same and 
Pharmaceutical 
Compositions hereof 
This invention relates to novel herbal 
anticancer agents. 
Sphaeranthus Various cancer 
Anticancer effect 
[28] 
US20090258096, 
10/15/2009 
Anticancer Methods 
Employing Extracts of 
Gleditsia sinensis Lam 
Selective apoptotic extracts of Gleditsia 
sinensis Lam are provided. Also provided 
are methods of using said extracts to induce 
apoptosis in specific cells, especially in a 
human. 
Oleanolic acid 
and saponin 
Breast cancer 
Estrogen receptor 
(ER) negative breast 
cancer. Apoptosis 
[29] 
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(Table 2)  Contd…. 
 
Patent Number, 
Date of Publication 
Title Description of Patent 
Extracts, 
Fractions and 
Active 
Constituents 
Cancer types, 
Mechanism of 
Anticancer Action; 
Cancer Types 
Reference 
US6790464, 
09/14/2004 
Herbal compositions for 
prostate conditions 
The invention provides a composition 
having beneficial effects in preventing and 
treating prostate disorders including 
prostatitis, benign prostate hyperplasia and 
prostatic carcinoma. 
Radix Asparagi Prostate cancer 
preventing and 
treating prostate 
disorders including 
prostatic carcinoma 
[30] 
US7618661, 
11/17/2009 
Process for preparation 
of Rhus verniciflua 
extracts having 
excellent anti-cancer 
activity and anti-cancer 
pharmaceutical 
composition containing 
the same 
Provided is a process for preparation of a 
Rhus verniciflua extract, thereby obtaining 
extract powder and irradiating far-infrared 
to the extract powder, thereby improving 
anti-cancer activity. 
Allergensremov
ed Rhus 
verniciflua 
extracts 
Various cancer 
cytotoxicity 
[31] 
US6660309, 
12/09/2003 
Antitumor agent A composition is obtained from Banyan 
tree bark that has insulin antisecretory and 
cytotoxic properties. 
Banyan tree 
bark fraction 
Various cancer 
cytotoxicity 
[32] 
US7250180, 
07/31/2007 
Anti-prostate cancer 
composition and 
therapeutic uses therefor 
The invention is based on BIRM, an extract 
of the plant Solanaceae-Dulcamara and its 
previously unrecognized anti-prostate 
cancer activity. Also disclosed are methods 
for preparing compositions for 
administration to humans for treating 
prostate cancer. 
Extract of 
Solanaceae- 
Dulcamara 
Prostate cancer 
Anti-prostate 
cancer, cytotoxicity 
[33] 
US20040043083, 
03/04/2004 
Anticancer composition 
comprising 
sesquiterpenes isolated 
from resina ferulae 
A pharmaceutical composition exhibits a 
potent anticancer activity. 
Sesquiterpenes Lung cancer, ovary 
cancer and so on 
Inhibition of 
proliferation. 
[34] 
US20030165579, 
09/04/2003 
Euphorbia antiquorum 
extract, a 
pharmaceutical 
composition containing 
the same and methods 
for treatment of cancers 
An herbal extract of Euphorbia antiquorum 
is provided. The herbal extract of the 
invention demonstrates in vitro inhibition of 
growth of hepatoma cells, colorectal 
adenocarcinoma cells, monocyte-like 
lymphoma and leukemia cells. 
Euphorbia 
antiquorum 
extract 
Liver cancer and 
colon cancer 
cytotoxicity 
[35] 
US7285571, 
10/23/2007 
Herbal chemical 
composition for the 
treatment of cancer 
The present invention relate to a novel 
synergistic composition of lignans 
exhibiting anticancer activities for breast, 
cervix, neuroblastoma, colon, liver, lung, 
mouth, ovary and prostate cancer. 
(?)-
Matairesinol, 
(?)-
Wikstromol, 
Dibenzylbutyrol
actol 
 
Various cancer 
cytotoxicity 
[36] 
US7078063, 
07/18/2006 
Water soluble extract 
from plant of Solanum 
genus and the 
preparation process 
thereof, and 
pharmaceutical 
composition containing 
the water soluble extract 
A water soluble extract from a plant of 
Solanum genus consists essentially of at 
least 60%–90% of solamargine and 
solasonine. The water soluble extract can be 
used as an active component in a 
pharmaceutical composition for inhibiting 
the growth of tumor/cancer cells, in 
particular liver cancer cells, lung cancer 
cells and breast cancer cells. 
solamargine 
and solasonine 
Liver cancer, lung 
cancer and breast 
cancer 
cytotoxicity 
[37] 
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(Table 2)  Contd…. 
 
Patent Number, 
Date of Publication 
Title Description of Patent 
Extracts, 
Fractions and 
Active 
Constituents 
Cancer types, 
Mechanism of 
Anticancer Action; 
Cancer Types 
Reference 
US6902748, 
06/07/2005 
Medicines 
manufactured from old 
platycodon extracts 
The present invention relates to anticancer 
agents, of which medical treatment 
materials are extracted from 20-year (or 
older) perennial old platycodon (i.e., old 
platycodon). 
Old Platycodon 
extract 
Various cancer 
cytotoxicity 
[38] 
US6613754, 
09/02/2003 
Polysaccharide-based 
extract from ganoderma, 
pharmaceutical use 
thereof, and process for 
preparing the same 
The polysaccharide-based extract of 
ganoderma genus can be used in an orally 
active medicinal product which has 
immunopotentiating and antitumoral 
effects. 
Polysaccharide-
based extract 
Various cancer 
cytotoxicity 
[39] 
US7201928, 
04/10/2007 
Extracts of orange peel 
for prevention and 
treatment of cancer 
Compositions and methods of inhibiting 
tumor cell growth and treating and 
preventing cancer are provided based on 
administration of an orange peel extract 
either alone or in combination with other 
phytochemicals. 
Flavone 
components 
Various cancer 
inhibitory effects of 
cell proliferation 
[40] 
US20080207578, 
08/28/2008 
Method of inducing 
apoptosis in cancer 
treatment by using 
Cucubritacins 
This invention relates to the preparation and 
use of anti-cancer compounds/formulation 
containing cucurbitacins. 
Cucurbitacins Various cancer 
induces apoptosis 
[41] 
US7033617, 
04/25/2006 
Use of Anoectochilus 
formosanus plant 
extracts and their 
derived fractions as 
herbal medicines or 
nutraceutical 
supplements for 
chemoprevention or 
treatment of human 
malignancies 
The present invention provides medicinally 
active extracts and fractions, and a method 
for preparing the same by extracting and 
fractioning constituents from the tissue of 
plant components of the Anoectochilus 
family. These active extracts and fractions 
are useful for preventing or inhibiting tumor 
growth. 
Crude or 
fraction of 
Anoectochilus 
formosanus 
Hayata 
Various cancer 
apoptosis, in vivo 
tumor growth 
inhibition 
[42] 
US20060280817, 
12/14/2006 
Pharmaceutical 
composition useful for 
the treatment of 
hepatocellular 
carcinoma 
The present invention relates to anticancer 
activity against hepatocellular carcinoma of 
an extract and fraction isolated from 
flowers of Butea monosperma. 
Flavonoid 
glycosides such 
as butrin and 
isobutrin 
Anti-hepatocellular 
carcinoma via 
inhibition of 
oxidative stress and 
polyamine 
biosynthetic 
pathway 
[43] 
US6808724, 
10/26/2004 
Artemisolide compound 
isolated from the aerial 
parts of Artemisia 
sylvatica, isolation 
method, and use thereof 
The present invention relates to a novel 
compound isolated from Artemisia 
Sylvatica, expressed by the formula 1, a 
method of isolation, and its use thereof, and 
more particularly to a novel compound 
isolated from Artemisia Sylvatica, a method 
of isolation, and its use in inhibiting 
farnesyl transferase activity. 
Artemisolide Various cancer 
inhibiting farnesyl 
transferase activity 
[44] 
US7306817, 
12/11/2007 
Herbal composition for 
treating CD33+ acute 
and chronic myeloid 
leukemia and a method 
thereof 
A method of treating CD33+ acute and 
chronic myeloid leukemia in animals 
including humans, using fraction nos. 1 and 
9 obtained from water. 
3-O-p-coumaryl 
quinic acid 
Leukemia, 
destruction of CD33 
+ myeloid leukemic 
cells 
[45] 
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Patent Number, 
Date of Publication 
Title Description of Patent 
Extracts, 
Fractions and 
Active 
Constituents 
Cancer types, 
Mechanism of 
Anticancer Action; 
Cancer Types 
Reference 
US20050175623，08
/11/2005 
Saponins as anticancer 
agent 
The invention described herein 
encompasses novel discovery of anticancer 
agents and its compositions comprising 
saponins, a group of triterpenoid and 
steroidal saponins found in plants including 
Quillaja saponaria Molina (soap tree). 
A group of 
triterpenoid and 
steroidal 
saponins 
Various cancer 
directly kill cancer 
cells through 
deconstruction of 
the cell membrane 
[46] 
US6451353, 
09/17/2002 
Fagopyrum cymosum 
(Trev.) Meisn 
composition, method to 
prepare and analyze the 
same and uses thereof 
This invention provides different 
compositions extracted from Fagopyrum 
cymosum (Trev.) Meisn. Said compositions 
comprise active components for therapeutic 
applications in treating lung cancer, gastric 
cancer, cervical cancer, sarcoma and other 
neoplasms. 
Tannins and 
procyanidins 
Various cancer 
Anticancer and 
reduce adverse 
effects associated 
with chemotherapy 
and radiotherapy 
[47] 
US20100028472, 
02/04/2010 
Herbal composition and 
process for its 
preparation 
A herbal composition comprising a 
therapeutically effective amount of the 
extract of Piper betle leaves as an active 
ingredient either alone, or with a 
pharmaceutically acceptable excipient. A 
significant invention in the art of cancer 
particularly leukemia. 
Extract of Piper 
betle leaves 
Leukemia. 
Against the Bcr- 
Abl mutated 
imatinib- 
resistant cell lines. 
[48] 
US20040116394, 
06/17/2004 
Method for treating 
cancer using betulinic 
acid rich herbal extract 
This invention relates to an orally effective 
herbal extract-based composition having 
broad-spectrum anticancer activity. Inhibits 
Protein Kinase C activity of cancer cells 
and induces apoptosis. 
Zizyphus Various cancer 
Apoptosis 
[49] 
US20060034951, 
02/16/2006 
Active fraction having 
anti-cancer and anti-
metastasis isolated from 
leaves and stems of 
ginseng 
Provided is a composition that contains, as 
an active ingredient, an extract or 
polysaccharides separated from the leaves 
and/or stems of plants belonging to Panax 
genus, for an anticancer drug or its 
adjuvant, 
Polysaccharides Various cancer 
Hemotopoiesis 
enhancement, 
cancer metastasis 
inhibition, bone 
marrow defense 
[50] 
US20040009244, 
01/15/2004 
Composition 
comprising Melissa leaf 
extract for anti-
angiogenic and matrix 
metalloproteinase 
inhibitory activity 
The present invention relates to a 
composition comprising Melissa leaf 
extract that inhibits angiogenesis and matrix 
metalloproteinase activity. 
Rosmarinic acid Various cancer 
Hnhibits 
angiogenesis and 
matrix 
metalloproteinase 
activity 
[51] 
US7709031, 
05/04/2010 
Angiogenic agents from 
plant extracts, gallic 
acid, and derivatives 
An extract of Chinese blackberry (Rubus 
suavissimus) has been found to inhibit 
angiogenesis, and two active fractions 
isolated. 
Various 
derivatives of 
gallic acid 
Various cancer 
antiangiogenesis 
[52] 
US6649185, 
11/18/2003 
Herbal formulation This invention relates to a new herbal 
formulation which has been found to be 
effective for the treatment of cancer. More 
particularly, the formulation can be used to 
treat haematological malignancies. 
Tinospora 
cordifolia and 
Aloa vera (Aloa 
barbedensis) 
Various cancer 
Haematological 
malignancies 
[53] 
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Patent Number, 
Date of Publication 
Title Description of Patent 
Extracts, 
Fractions and 
Active 
Constituents 
Cancer types, 
Mechanism of 
Anticancer Action; 
Cancer Types 
Reference 
US5876728, 
03/02/1999 
Natural composition 
extracted from plants 
used in the treatment of 
cancer 
The invention is a method of treating cancer 
comprising administering an effective 
amount of either a composition of three 
herbal extracts consisting essentially of 
Goldenseal, Myrtle, and Centaurea. 
Extract of three 
herbs or seven 
herbs in a 
mixture of water 
and ethyl ether 
Various cancer 
Cytotoxicity 
[54] 
US5437866, 
08/01/1995 
Herbal treatment of 
malignancy 
A protocol using natural extracts which 
permit amelioration of malignancies in 
humans is disclosed. The protocol 
mandatorily includes an extract of Lentinus 
edodes and mung beans, and optionally 
further includes the combined extract of 
Hedyotis diffusa and Scutellaria barbata. 
Extracts of 
Letinus edodes, 
mung bean, 
Hedyotis diffusa 
and Scutellaria 
barbata 
Various cancer 
in vivo tumor 
growth inhibition 
[55] 
US6936284, 
08/30/2005 
Composition having 
anticancer activity 
To conduct a search for natural drugs and 
their formulae derived from natural 
substances that hardly cause side effects 
and drug tolerance, based on quite a new 
idea having departed from conventional 
drugs. 
A dry product of 
Angelica keiskei 
and/or a dry 
product of 
Theaceae 
Camellia 
Various cancer 
An anticancer 
activity and is 
selectively 
cytotoxic to cancer 
cells 
[56] 
US20080280839, 
11/13/2008 
Anti-Cancer Activity of 
Androsace Umbellata 
Merr. Extract and 
Contained Triterpene 
Saponin 
The present invention relates to an 
Androsace umbellata Merr. extract having 
anticancer activity and a triterpene saponin 
compound isolated therefrom. 
Androsace 
umbellata (Lour.) 
Merr. extract, 
saxifragifolin B 
and saxifragifolin 
D 
Various cancer 
Inhibits cancer cell 
growth and induces 
apoptosis 
[57] 
US20050058722, 
03/17/2005 
Herbo-mineral 
formulation for 
refractory leukemias 
and lymphomas 
A pharmaceutical or medicinal preparation 
comprising a mixture of arsenic trioxide 
(As2O3) and the herbs Aloe Vera (Aloe 
Barbedensis), Withania Somnifera, Glycine 
Max, Rubia Cordifolia and Acacia Catechu, 
or a mixture of the active ingredients that 
have been extracted from those herbs. The 
herbo-mineral formulation of the invention 
is effective for the treatment of cancer, in 
particular refractory leukemias 
Arsenic trioxide 
and other five 
herbs, 
Leukemia and 
kymphoma 
Refractory 
leukemias 
Apoptosis 
[58] 
US20070082072, 
04/12/2007 
Herbal Composition for 
Treating Cancer 
The present invention relates to an herbal 
composition that provides anti-cancer 
effects, especially for breast cancer. 
Wubeizi, Lonicerajaponica, Astragalus 
membranaceus, Rehmanniae Radix, 
Glycyrrhizae Radix and Panax schinseng. 
6 Herbal 
Composition 
Various cancer 
Apoptosis 
[59] 
US20050208070, 
09/22/2005 
Compositions of 
botanical extracts for 
cancer therapy 
Methods and compositions for prevention 
and therapy of cancer are provided. 
Compositions comprising therapeutically 
effective amounts of two or more of an 
extract of Ganoderma lucidum, an extract 
of Salvia miltiorrhiza and an extract of 
Scutellaria barbata and optionally a 
therapeutically effective amount of an 
extract of Hippophae rhamnoides are 
provided. 
Extracts of said 3 
herbs, and 
optionally, 
Hippophae 
rhamnoides (sea 
buckthorn) 
Various cancer 
Cytotoxicity, Cox-2 
inhibition 
[60] 
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Patent Number, 
Date of Publication 
Title Description of Patent 
Extracts, 
Fractions and 
Active 
Constituents 
Cancer types, 
Mechanism of 
Anticancer Action; 
Cancer Types 
Reference 
US20080233218, 
09/25/2008 
Methods for treating 
oral cancers with herbal 
compositions 
The inventive subject matter relates to 
methods for treating oral cancers, 
comprising administration of a composition 
comprising therapeutically effective 
amounts of supercritical extracts of 
rosemary, turmeric, oregano and ginger. 
Hydroalcoholic 
extracts of said 
9 herbs 
Various cancer 
Anti-oral cancers 
via modulating gene 
expression 
[61] 
US20070160691, 
07/12/2007 
Pharmaceutical 
composition for treating 
and preventing cancer 
comprising cinnamoni 
cortex extract and 
zizyphi fructus extract 
Disclosed is a pharmaceutical composition 
for treating and preventing cancer, 
comprising a Cinnamoni Cortex extract and 
a Zizyphi Fructus extract.. 
Cinnamoni 
Cortex extract 
and a Zizyphi 
Fructus extract 
Various cancer 
Induces apoptosis 
and inhibits 
metastasis 
[62] 
US6780441, 
08/24/2004 
Composition of eleven 
herbals for treating 
cancer 
The herbal formulation of the invention is 
effective for the treatment of cancer, in 
particular squamous cell carcinomas, 
tumours and other metastatic states, 
including lung cancer. 
A mixture of 11 
herbal extract 
Squamous cell 
carcinomas 
Anti-metastasis 
[63] 
US20060216366, 
09/28/2006 
Herbal compositions 
useful in cancer 
treatment 
The composition can be processed into a 
form for administering to human patients 
with a cancerous disease for improving 
their health. 
4 Herbal 
compositions 
Various cancer 
Anti-metastasis 
[64] 
 
have similar anticancer action with single pure compounds 
by their cytotoxicity, inhibition of cancer growth and proli-
feration, as well as suppression of cancer invasion and 
metastasis in forms of extract or fraction from single or 
combination herbs [26-64]. Most of the studiese were 
conducted in in vitro system, leaving the problem that if 
these extract and fractions could be effective in vivo and in 
clinical practice. Also, the quality assurance of the herbal 
extract and fraction is the major problem needed to be 
carefully concerned. First of all, since the products are 
always extracted from the herbs, the difference from batch to 
batch of the herb should be carefully checked during 
manufacturing. The secondary metabolites that herbs contain 
may be affected by the growth conditions of the plants, such 
as light, water and nutrients. Therefore, a Good Agriculture 
Practice (GAP) standard should be required for each kind of 
medical plant and the GAP base for each herb should be 
addressed. The herbs used in botanical drug production 
should come from the GAP base. Second, the manufacturing 
process of the herbal drug should be under restricted and 
real-time control. It is highly recommended that drug 
investigator should well document the manufacturing 
process in their pre-clinical study of the drug, which may 
include good and reasonable optimization of the extraction 
process, careful validation and some minor adjustments on 
the process from bench-top to manufacturing. And the 
production of herbal should follow the guideline of Good 
Manufacturing Practice (GMP). These will ensure the 
stability and reproducibility of the herbal drugs. And at last 
but not the least, the quality control document should be well 
prepared by the drug investigators during the pre-clinical 
studies. This may include isolation and identification of 
major compounds, establishment and optimization of che-
mical analysis system for the raw herbs, the manufacturing 
process and the final products. In China, the State Food and 
Drug Administration (SFDA) requires that the identified 
compounds should comprise at least more than 50% of the 
herbal extract, and it will be highly recommended that 
chemical analysis and quality assurance may be carried out 
in more than one approach. Combined approaches for the 
qualitative and quantitative analysis of the product will 
increase the success rate of drug application. The scheme of 
basic production process of herbal drugs, including pure 
compounds and fractions/extracts, is shown in Fig. (1). 
COMBINATION OF HERBAL PRODUCT AND 
CHEMO- AND RADIO-THERAPY AND THE HERB-
DRUG INTERACTION IN CANCER THERAPY 
 Conventional cancer therapies have surgical resection, 
chemotherapy and radiotherapy. Chemotherapeutants and 
radiotherapy may cause severe toxicity. Common adverse 
effects associated with cancer chemotherapy include gastro-
intestinal complications (e.g., diarrhea, nausea, vomiting, 
anorexia and mucositis), appetite loss, bone marrow/ 
hematological complications (e.g., leukopenia, neutropenia, 
anemia, hemorrhage, and thrombocytopenia), fatigue, weight 
loss, insomnia, pain and even life threat etc. These symptoms 
not only affect the quality of life, but also reduce the tole-
rance and response to anti-cancer drugs, thereby affecting the 
prognosis and survival to disease. How to improve the 
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situations of cancer patient ongoing or after conventional 
cancer therapies is a great challenge. For these purposes, 
various extracts or fractions in the US patent (granted or 
under application) from single or composite medicinal herbs 
are listed in Table 3. These various extracts or fractions used 
in combination therapy claimed that herbal medicines can 
enhance therapeutic index or reduce side effects of the 
chemotherapeutic drugs [65-73]. However, there's a lack of 
clinical studies for confirming the claims at clinical level. 
 Herb-drug interactions are complicated issues. The 
interaction of herb and drug may increase the drug action or 
decrease it. This may depend on the complication system of 
drug metabolism enzymes in human body. Herbal products 
may activate or suppress the CYPs activities which will 
result in changes in the pharmacokinetics of the drug, 
including the changes in bio-availability, the metabolite of 
the drug and the excretion rate. In particular, if the drugs are 
designed in a pro-drug form, which should be preliminary 
metabolized before it could take action, this kind of 
interaction may directly affect the drug effect. In Table 4, we 
summarized herb-herb or drug interactions in forms of 
extract or fractions from single herbs which are claimed to 
increase bioavailability and/or bioefficacy of anticancer 
drugs. These patents disclosed beneficial effects for anti-
cancer drugs when combining anticancer drugs with 
indicating extract or fractions though most of the studies 
conducted in in vitro and in vivo studies [74-79].  
 Herbal medicine is a multi-component system with 
complication and unclear composition, among which partial 
compounds are responsible for the anticancer effect. In the 
past years, many novel separation techniques with significant 
advantages over conventional methods have been introduced 
and applied to separation and analysis of the chemical cons-
tituents of anticancer in herbal medicines. It is still a 
challenge for preparing a pharmaceutical formulation 
containing two or more active anticancer ingredients or 
isolating specific anticancer active constituents from herbal 
medicines. In Table 5, we choose three patents which dis-
closed the process for preparing pharmaceutical formulations 
using supercritical fluids and fermenting panax genus plant 
or panax notoginseng solution with anticancer effects [80-
82].  
CLINICAL TRIAL 
 Not as many as the patents approved, there are only a few 
of clinical studies focusing on the anti-tumor effect of herbal 
medicines [83-100]. To sort them by their locations, it is 
noticed that the major part of these clinical trials is 
conducted in United States (13 in 18). For the other parts, 2 
are carried out in Canada, 1 in Taipei, 1 in India, and 1 in 
South Africa. It is interesting to find that though China is the 
origin of the use of herbal medicines in clinical practice, it is 
United States where most of the clinical trials choose to be 
carried out. It is somehow a good point to see some of these 
clinical trials are under restricted regulation and double-
blind, randomized, placebo-controlled conditions, which 
may put out more reliable results to draw conclusion of the 
herbal medicine’s action. To sort by their progress, it could 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The overall scheme of the development of a patented herbal drug by quality control. 
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Table 3. Various Extracts or Fractions Used in Combination Therapy of Herbal Medicines and Drugs. 
Patent Number, 
Date of 
Publication 
Title Description of Patent 
Extracts, Fractions 
and Active 
Constituents 
Reference 
US20090130101, 
05/21/2009 
anti-cancer therapy with an 
extract of Scutellria Barbata 
Methods of treating cancer with a combination of an extract of 
Scutellaria barbata D. Don and at least one additional 
anticancer chemotherapeutic agent are provided. 
Extract of Scutellaria 
barbata D. Don 
[65] 
US20080311230, 
12/18/2008 
Preparation of Artemisia to 
treat human cancer, 
autoimmune disease, IgA-
Nephropathy, and to 
counteract weight loss in 
cancer patients 
Anti-cancer drugs that were effective in the beginning start 
losing their efficacy, and are less tolerated. Also in 
autoimmune diseases, the immune system is overreacting. 
This herbal invention, based on Artemisia species, ginger root 
and large cardamom, each targeting at different factors 
involved in weight loss and autoimmune diseases, is effective 
Artemisia oils and 
other 2 herbs 
[66] 
US7407675, 
08/05/2008 
Anti-neoplastic 
compositions comprising 
extracts of black cohosh 
The present invention further provides a combination of anti-
neoplastic agents, comprising an effective anti-neoplastic 
amount of an ethyl acetate extract of black cohosh and an 
effective anti-neoplastic amount of at least one additional 
chemopreventive or chemotherapeutic agent. Methods for 
treating and preventing neoplasia are also provided. 
Ethyl acetate extract of 
black cohosh 
[67] 
US6432454, 
08/13/2002 
Processes of making north 
american ginseng fractions, 
products containing them, 
and use as 
immunomodulators 
The invention is directed to chemical processes of preparing 
fractions from North American ginseng (Panax 
quinquefolium) and pharmaceutical compositions containing 
these fractions. The products of the present invention may be 
used to stimulate the production of cytokines and/or 
antibodies, or as therapeutics targeted at conditions 
characterized by low immunity, such as the common cold, 
influenza, chronic fatigue syndrome, AIDS and cancer. 
Polysaccharide [68] 
US7192612, 
03/20/2007 
Compositions and methods 
based on synergies between 
capsicum extracts and tea 
catechins for prevention and 
treatment of cancer 
The invention described herein encompasses methods and 
compositions of preventing or treating cancer comprising the 
administration of a combination of therapeutically effective 
amount of catechins, a group of polyphenols found in green 
tea, and Capsicum extracts. The invention also encompasses 
the varying modes of administration of the therapeutic 
compounds, including a formulation which may be used as a 
therapeutic compound for the treatment of cancer or as a 
dietary supplement for the prevention of cancer. 
Epigallocatechin 
gallate (EGCg), 
epicatechin (EC), 
epicatechin gallate 
(ECG), 
epigallocatechin 
(EGC) 
[69] 
US6713093, 
03/30/2004 
Antialopecia agent The present invention provides an antialopecia agent which is 
a drug for protecting, reducing or preventing alopecia 
frequently occurring as the side effect of anticancer agents. 
Oolong tea extract [70] 
US20040197427, 
10/07/2004 
Herbal composition for 
improving anticancer 
activity, immune response 
and hematopoiesis of the 
body, and protecting the 
body from oxidative 
damage, and the method of 
preparing the same 
Disclosed is a herbal composition comprising a first hot-water 
extract from a mixture of the plants. 
Polysaccharide fraction [71] 
US20080213386, 
09/04/2008 
Nutraceutical for the 
prevention and Treatment of 
Cancers and Diseases 
affecting the liver 
The composition can be taken as a daily dietary supplement to 
enhance normal physiological functions of the body. The 
compositions are also useful for administration to patients 
with pre-existing hepatitis and/or liver cirrhosis. The 
compositions or extracts thereof may be useful for treating 
other cancers and other disorders, diseases, or conditions. 
Vitamins and nutrients 
that provide a novel 
nontoxic treatment for 
liver cancers, hepatitis, 
and liver cirrhosis. 
[72] 
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Patent Number, 
Date of 
Publication 
Title Description of Patent Extracts, Fractions 
and Active 
Constituents 
Reference 
US7025993, 
04/11/2006 
Herbal composition 
PHY906 and its use in 
chemotherapy 
The present invention relates to herbal compositions and 
herbal extracts useful for increasing the therapeutic index of 
drugs, including those used in the treatment of disease, 
especially viral infections and neoplasms of cancer. 
Furthermore, this invention improves the treatment of disease 
by increasing the therapeutic index of chemotherapy drugs by 
administering the herbal composition PHY906 to a person 
undergoing such chemotherapy. 
Four herbal 
composition 
[73] 
 
Table 4. Herb-herb or Drug Interactions in Forms of Extract or Fractions from Single Herbs Increase Bioavailability and/or Bio-
efficacy. 
Patent Number, 
Date of 
Publication 
Title Description of Patent 
Extracts, 
Fractions and 
Active 
Constituents 
Indication in 
Cancer 
Therapy 
Reference 
US20040052873, 
03/18/2004 
Bioavailability / bioefficacy 
enhancing activity of 
cuminum cyminum and 
extracts and fractions 
thereof 
The present invention is directed to 
preparation of active extracts/fraction from the 
plant Cuminum cyminum and methods of 
using such products to enhance bioavailability 
and/or bioefficacy of anti-cancer drugs, 
natural products and essential nutraceuticals. 
Extract and 
fractions of 
cuminum cyminum 
Enhancing the 
bioavailability 
of anti-cancer 
drug 
[74] 
US20100112101, 
05/06/2010 
Bio-availability/bio-efficacy 
enhancing activity of Stevia 
Rebaudiana and extracts and 
fractions and compounds 
thereof 
The present invention discloses novel 
bioenhancing agents comprising raw powder 
or extract or active fraction(s) or compound(s) 
derived from genus Stevia preferably Stevia 
rebaudiana leaf, to potently enhance the bio-
availability and bio-efficacy of a number of 
anticancer drugs. 
Extract or active 
fraction(s) or 
compound(s) 
derived from 
genus Stevia 
preferably Stevia 
rebaudiana leaf 
Enhancing the 
bioavailability 
and bio-efficacy 
of anti-cancer 
drugs 
[75] 
US20060057234, 
03/16/2006 
Composition comprising 
pharmaceutical/nutraceutical 
agent and a bio-enhancer 
obtained from Glycyrrhiza 
glabra 
The invention relates to a new use of a non-
alkaloid compound that is plant derived 
glycoside ‘glycyrrhizin’ as a highly potent 
bio-enhancer of activity and availability of 
antibiotics and other drugs including anti-
infective and anticancer agents. 
Non-alkaloid 
compound that is 
plant derived 
glycoside 
‘glycyrrhizin’ 
bio-enhancer 
and 
bioavailability 
facilitator for 
anti-cancer 
drugs 
[76] 
US5653981, 
08/05/1997 
Use of nigella sativa to 
increase immune function 
A pharmaceutical composition for treatment of 
cancer and other conditions and the prevention 
of side effects of anticancer chemotherapy and 
increasing the immune function contains an 
extract of the plant Nigella sativa. 
Plant seed extract 
of Nigella sativa 
Linn (N. sativa) 
Prevention of 
side effects of 
anticancer 
chemotherapy 
and increasing 
the immune 
function 
[77] 
US20050214390, 
09/29/2005 
Bioavailability enhancing 
activity of Carum carvi 
extracts and fractions 
thereof 
The present invention relates to the use of 
extracts of Carum carvi as bioenhancers, 
either alone or in combination with piperine or 
Zinzeber officinale extract to improve the 
bioavailability of a wide variety of drugs. 
Carum carvi 
extract or fraction 
Bioavailability 
enhancer 
[78] 
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Patent Number, 
Date of 
Publication 
Title Description of Patent Extracts, Fractions 
and Active 
Constituents 
Indication in 
Cancer 
Therapy 
Reference 
US6617335, 
09/09/2003 
Preparation and drug 
composition of bis-
benzyl-isoquinoline class 
alkaloids 
This invention relates to the preparation of bis-
isoquinoline derivatives of general formula (I) 
and salts thereof, which possesses multi-drug 
resistance (MDR) reversal activities. Drug 
compositions and formulations comprising bis-
isoquinoline derivatives of general formula (I) 
and salts thereof are provided for use as 
sensitivity enhancers in cancer chemotherapy. 
Methods for inhibiting MDR by treatment with 
bis-isoquinoline derivatives are also provided. 
Bis-isoquinoline 
derivatives 
Multi-drug 
resistance 
(MDR) 
reversal 
activities 
[79] 
 
Table 5. New Patented Techniques in Chemical Isolation and Analysis. 
Patent Number, 
Date of 
Publication 
Title Description of Patent Reference 
US20040202681, 
10/14/2004 
Process for 
preparing 
pharmaceutical 
formulations using 
supercritical fluids 
The invention is directed to a process for preparing a pharmaceutical formulation containing 
two or more active pharmaceutical ingredients comprising: (a) contacting two or more active 
pharmaceutical ingredients with a supercritical fluid to form a supercritical fluid solution; and 
(b) separating the active ingredients from the supercritical solution to yield a powder 
precipitate. 
[80] 
US20030190378, 
10/09/2003 
Extract of processed 
Panax genus plant, 
the preparation 
method thereof, and 
compositions 
containing the same 
The present invention relates to an extract of processed Panax genus plant, the preparation 
thereof and compositions containing the same having anticancer or anti-allergic activity. Panax 
genus plants and subsequent bio-converting treatment such as lactic fermenting and intestinal-
bacterial fermenting process so as to make a ratio of ginsenoside 
(Rk2+Rh3+protopanaxadiol+20-dehydroprotopanaxadiol) to (Rg3+Rg5+Rk1) of above 0.1. The 
extract of processed Panax genus plant in the present invention has inhibitory effect for cancer 
or allergic diseases and it is useful in the prevention or treatment of cancer or allergic diseases. 
[81] 
US20080220100, 
09/11/2008 
Fermented Panax 
notoginseng 
solution with anti-
cancer effects and 
manufacture method 
thereof 
This invention relates to a fermented Panax notoginseng solution and manufactured method 
thereof. The manufacture method comprises activating a Lactobacillus spp, fermenting a Panax 
notoginseng medium with the Lactobacillus spp. to form a fermented solution, and centrifuging 
the fermented solution to obtain a supernatant. The supernatant has anti-cancer effects. 
[82] 
 
be observed that most of the studies are carried out in phase 
II clinical trial, which assess how well the drug works in 
patients. One drug is undertaken in phase III clinical trial and 
one is in post-marketing stage. 7 of the studies also carry out 
Phase I clinical trial to assess the safety of the herbal 
materials, which may be under critical concerns for the use 
of herbal medicines. Interestingly, there’s noclinical study 
focusing on the direct anti-tumor activity of the herbal 
medicine, which is contradictory with the patent affairs, 
where many patents reported anti-tumor effect of the herbal 
drugs. The major purpose of herbal medicine intervention in 
these clinical trials is to reduce the adverse effect of chemo- 
or radio-therapy, to give a support care to cancer patients, 
and to increase the quality of life of the patients. Prevention 
of tumorigenesis by herbal medicines is also under 
investigation. This contradiction leads us to think about the 
future use of patents reporting anti-tumor activity of herbal 
medicines, and it may criticize the accreditation process of 
patent application in the world. Should we need more 
restricted criteria in the assessment to the patent application 
materials? And should the operability of the patent in clinical 
trials be in prior considered in the assessment to the patent 
application? These questions need to be taken into consi-
deration by both investigators and administrative depart-
ments. The detail information about clinical trials conducted 
for herbal medicine in the treatment of cancer is listed in 
Table 6. 
CURRENT & FUTURE DEVELOPMENTS  
 Herbal medicines can be used in some countries based on 
both scientific and culture aspects. It may be a world-wide 
phenomenon that the use of herbal medicines depends on 
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Table 6. Herbal Medicine Under Clinical Trials. 
Title Location Phase Allocation Control Masking Drug Reference 
Compound Herbal Formula (TPE-1) for 
Leukopenia and Cancer-related Fatigue 
in Breast Cancer Patients With 
Radiotherapy 
Taipei phase II, 
phase III 
Randomized Dose 
comparison 
Double 
Blind 
Compound Herbal 
Formula (TPE-1) 
[83] 
Iscar for Supplemental Care in Stage IV 
Lung Cancer 
US Phase II Non-
Randomized 
Dose 
comparison 
Open 
Label 
Iscar is an herbal 
medicine made from 
the total plant extract 
of mistletoe. 
[84] 
Boswellia Serrata and Standard 
Treatment or Standard Treatment Alone 
in Treating Patients Who Have 
Undergone Surgery and Radiation 
Therapy for Newly Diagnosed or 
Recurrent High-Grade Glioma 
US Phase II Randomized Active 
Control 
not clear Boswellia serrata [85] 
A Clinical Study of PHY906 as a 
Modulator of CPT-11 in Patients With 
Metastatic Colorectal Cancer 
US Phase I, 
Phase II 
not clear Single Group 
Assignment 
Open 
Label 
PHY906 [86] 
Sho-Saiko-To Following Removal of 
Liver Cancer By Embolization in 
Treating Patients With Liver Cancer 
That Cannot Be Surgically Removed 
US Phase II N/A N/A N/A Sho-saiko-to [87] 
Safety and Pharmacokinetics of Jin Fu 
Kang in Comb w/Docetaxel for Patients 
w/Non-Small Cell Lung Cancer 
US Phase II Non-
Randomized 
uncontrolled Open 
Label 
Jin Fu Kang [88] 
Ginger Control of Chemotherapy 
Induced Nausea and Vomiting 
US Phase II Randomized Placebo Double 
Blind 
Ginger [89] 
Combination Chemotherapy After 
Surgery With or Without Chinese Herbal 
Therapy to Treat Symptoms in Women 
With Breast Cancer 
US Phase I, 
Phase II 
Randomized Placebo Double 
Blind 
Chinese herbal 
therapy (CHT) 
[90] 
Survey of the Use of Alternative Medical 
Therapies in Adult Cancer Patients 
Enrolled in Phase I Clinical Trials 
US Phase I N/A N/A N/A Alternative Medical 
Therapies 
[91] 
Treatment of Anal High-grade Squamous 
Intraepithelial Lesions (HSIL) Through 
Use of a Chinese Herbal Topical Cream 
(AIJP) 
US Phase II Randomized Placebo Double 
Blind 
AIJP (Arnebia 
Indigo Jade Pearl) 
[92] 
Study of Botanical PHY906 Plus 
Capecitabine for Advanced Unresectable 
Hepatocellular Carcinoma 
US Phase I, 
Phase II 
Non-
Randomized 
Historical 
control 
Open 
Label 
PHY906 [93] 
ACAPHA in Preventing Lung Cancer in 
Former Smokers With Bronchial 
Intraepithelial Neoplasia 
Canada Phase II Randomized Placebo Double 
Blind 
multi-herbal agent 
ACAPHA 
[94] 
Pycnogenol for the Treatment of 
Lymphedema of the Arm in Breast 
Cancer Survivors 
US Phase II Randomized Placebo Double 
Blind 
Pycnogenol [95] 
Siliphos in Advanced Hepatocellular 
Carcinoma 
US Phase I Non-
Randomized 
N/A Open 
Label 
siliphos [96] 
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(Table 6) Contd…. 
 
Title Location Phase Allocation Control Masking Drug Reference 
Trial of Blue Citrus Compared to 
Placebo in Patients Receiving Aromatase 
Inhibitor Therapy for Estrogen Receptor 
Positive Post-Menopausal Breast Cancer 
US Phase II Randomized Placebo Double 
Blind 
Blue Citrus [97] 
Angelica Sinensis for the Treatment of 
Hot Flashes in Men Undergoing LHRH 
Therapy for Prostate Cancer 
Canada Phase IV Randomized Placebo Double 
Blind 
Angelica Sinensis [98] 
A Safety Study of Lessertia Frutescens in 
Adults 
South 
Africa 
Phase I Randomized Placebo Double 
Blind 
Lessertia frutescens 
(L.) Goldblatt & J.C. 
Manning (syn. 
Sutherlandia 
frutescens (L.) R. 
Br.) 
[99] 
Pilot Study of Curcumin Formulation 
and Ashwagandha Extract in Advanced 
Osteosarcoma (OSCAT) 
India Phase I, 
Phase II 
Non-
Randomized 
uncontrolled Open 
Label 
Curcumin 
Formulation, and 
Ashwagandha Root 
Powder Extract 
[100] 
 
traditional culture and lessons from the forerunners however, 
more and more scientific evidences have been obtained from 
in vitro studies and in animal models. The US patents have 
been issued for herbal compositions which were used in the 
treatment of cancer and cancer-related health problems in the 
past years. We believe such application for the US patent 
will be increased. In fact, as the world economic structure 
changes, the accumulated research results of herbal medi-
cines and market demand on the botanical drugs require 
more innovative knowledge for patent application [101]. In 
this review, a total of 15 single pure compounds and 57 
herbal compositions from single herbs or herbal mixture in 
the US patent (granted or under application) were reported 
for cancer types, anticancer mechanism, cancer-related 
health problems and the herbal preparation method etc. 
Although the patents listed in these tables do not cover all 
patent application situations, they represent some hot 
research materials and topics in herbal medicines and cancer 
research, for example, regarding anticancer effect of ber-
berine [7], saponins [8], curcumin [21] in Table 1, we can 
find over 43, 100 and 204 references respectively from 
PubMed (date of retrieving with key word as “berberine and 
anticancer”, “saponins and anticancer” and “curcumin and 
anticancer” was November 3, 2010).  
 69% of anticancer drugs approved were either natural 
products or developed based on knowledge gained from 
natural products between the 1980s and 2002 [102], which 
may indicate that drug development based on the com-
ponents with lead structures of potent bioactivity isolated 
from medical plants has been a major strategy for developing 
new anticancer drugs from herbal medicines. However, 
cancer is a genomic disease associated with multiple risky 
factors. There are six hallmarks for every type of cancer 
[103]: self-sufficiency in growth signals, resistance to 
growth inhibitory signals and anti-cancer therapy, evasion of 
programmed cell death, unlimited replication capability, sus-
tained ability of angiogenesis, and invasion and metastasis. 
The complicated pathology may require multi-targeted 
treatment in cancer therapy. In the Tables 2, 3 and 4. We 
summarized the extracts and fractions from herbal medi-
cines, whose therapeutic efficacy is based on the combined 
action of a mixture of constituents. These extracts and frac-
tions offer new treatment opportunities for cancer in multi-
components and multi-targets system. Theoretically, thera-
peutic principles for multi-components in the extracts and 
fractions involve bioavailability, interference with cellular 
transport processes, activation of pro-drugs or deactivation 
of active compounds to inactive metabolites, inhibition of 
binding to target proteins, action of synergistic partners at 
different points of the same signaling cascade or different 
signaling pathways. It is a pity that many of these extracts 
and fractions are not yet deeply studied.  
 Overviewing the listed patents in the tables, many 
patented single pure compounds and various extracts/ 
fractions from single or composite medicinal herbs are not 
yet used as drugs for anticancer. There is a long way to go 
before it becomes a new drug, even though it is just used as 
botanical drug products. However, these patented materials 
should not remain unused and more studies should be 
conducted to get portfolio patents to validate the anticancer 
application in clinical settings. To push deep studies for 
these products of the patents, we should focus on preclinical 
(quality, safety and efficacy) and clinical studies because the 
lack of pharmacological and clinical data on the majority of 
herbal medicinal products is a major impediment to the 
integration of herbal medicines into conventional medical 
practices [104]. Various "-Omics" technologies and systems 
biology may facilitate unravelling complicated and/or 
synergistic effects of herbal mixtures.  
 Invention and development of PHY906 [73] is a good 
example for new botanic drug from herbal medicines for 
increasing the therapeutic index of chemotherapy drugs by 
administering PHY906 to cancer patients undergoing 
chemotherapy. PHY906 is a composite formula consisting of 
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four Chinese medicinal herbs (Scutellaria baicalensis, 
Glycyrrhiza uralensis, Ziziphus jujuba, and Paeonia 
lactiflora). The first thing is how to guarantee the products in 
consistency from batch to batch. The inventers have spent as 
long as ten years to establish and continually improve the 
platform for quality control of PHY906 [105,106]. At the 
same time, the inventers did much work for mechanism of 
action and drug metabolism of PHY906 in in vitro and in 
vivo studies for gastrointestinal malignancies [107,108]. The 
inverters have also finished several phase I/ II clinical trials 
and demonstrated the potential benefit for advanced 
hepatocellular carcinoma, advanced pancreatic and other 
gastrointestinal malignancies in clinical settings [109,110]. 
This is the first composite formula from Chinese medicinal 
herbs to be used in carrying out the phase I/II clinical trials 
in the US and has been recognized with high international 
reputation [111]. We think these series research for PHY906 
will serve as a model for dietary supplements and botanical 
drug products from herbal medicines in terms of multi-
components, quality control, mechanism of action and drug 
metabolism and translational research.  
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